Initial commercial availability begins through an Early Experience Program with Penn Highlands Healthcare and Allegheny Health Network
SAN MATEO, Calif. — November 18, 2025 — PrognomiQ, a healthcare company focused on harnessing the power of proteomics and multi-omics data to transform the detection and early treatment selection and monitoring of cancer and other complex diseases, today announced the launch of ProVue Lung, a novel blood-based Laboratory Developed Test (LDT) designed to help improve detection of lung cancer at its earliest, most treatable stages.
Read the full article here.
